Cargando…
Cutting‐edge strategies for borderline resectable pancreatic cancer
Worldwide, pancreatic ductal adenocarcinoma (PDAC) accounts for more than 400 000 deaths every year, being the 12th most common cancer and the seventh most frequent cause of death from cancer. Regardless of the advances in diagnosis and treatment, PDAC continues to have dismal outcomes and fewer tha...
Autores principales: | Shinde, Rajesh S., Bhandare, Manish, Chaudhari, Vikram, Shrikhande, Shailesh V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635681/ https://www.ncbi.nlm.nih.gov/pubmed/31346575 http://dx.doi.org/10.1002/ags3.12254 |
Ejemplares similares
-
Portal Annular Pancreas (PAP): an Underestimated Devil in Pancreatic Surgery—Systematic Review of Literature and Case Report
por: Pandrowala, Saneya, et al.
Publicado: (2021) -
To Do or Not to Do?—A Review of Cancer Surgery Triage Guidelines in COVID-19 Pandemic
por: Shinde, Rajesh S., et al.
Publicado: (2020) -
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022) -
An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers
por: Bhargava, Prabhat, et al.
Publicado: (2022) -
Borderline resectable pancreatic cancer: Certainties and controversies
por: Nappo, Gennaro, et al.
Publicado: (2021)